{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:14:30Z","timestamp":1777396470763,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:p>Background: The Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial (ADAPT) was the first-ever large-scale anti-inflammatory prevention trial targeting Alzheimer\u2019s disease. Objective: The overall goal of this study was to evaluate predictive blood biomarker profiles that identified individuals most likely to be responders on NSAID treatment or placebo at 12 and 24 months. Methods: Baseline (n\u200a=\u200a193) and 12-month (n\u200a=\u200a562) plasma samples were assayed. The predictive biomarker profile was generated using SVM analyses with response on treatment (yes\/no) as the outcome variable. Results: Baseline (AUC\u200a=\u200a0.99) and 12-month (AUC\u200a=\u200a0.99) predictive biomarker profiles were highly accurate in predicting response on Celecoxib arm at 12 and 24 months. The baseline (AUC\u200a=\u200a0.95) and 12-month (AUC\u200a=\u200a0.9) predictive biomarker profile predicting response on Naproxen were also highly accurate at 12 and 24 months. The baseline (AUC\u200a=\u200a0.93) and 12-month (AUC\u200a=\u200a0.99) predictive biomarker profile was also highly accurate in predicting response on placebo. As with our prior work, the profiles varied by treatment arm. Conclusions: The current results provide additional support for a precision medicine model for treating and preventing Alzheimer\u2019s disease.<\/jats:p>","DOI":"10.3233\/jad-230317","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:18:36Z","timestamp":1694776716000},"page":"1609-1622","source":"Crossref","is-referenced-by-count":4,"title":["Precision Medicine for Preventing Alzheimer\u2019s Disease: Analysis of the ADAPT Study"],"prefix":"10.1177","volume":"95","author":[{"given":"Sid E.","family":"O\u2019Bryant","sequence":"first","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hall","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Petersen","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther S.","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA"},{"name":"Richman Family Precision Medicine Center of Excellence in Alzheimer\u2019s Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine G.","family":"Lyketsos","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA"},{"name":"Richman Family Precision Medicine Center of Excellence in Alzheimer\u2019s Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA"},{"name":"VA San Diego Healthcare System, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230317_ref1","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMsa1204629","article-title":"Monetary costs of dementia in the United States","volume":"368","author":"Hurd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230317_ref2","doi-asserted-by":"crossref","unstructured":"(2020) 2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 16, 391\u2013460.","DOI":"10.1002\/alz.12068"},{"key":"10.3233\/JAD-230317_ref3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-180619","article-title":"A precision medicine model for targeted NSAID therapy in Alzheimer\u2019s disease","volume":"66","author":"O\u2019Bryant","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230317_ref4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-201610","article-title":"A precision medicine approach to treating Alzheimer\u2019s disease using rosiglitazone therapy: A biomarker analysis of the REFLECT Trials","volume":"81","author":"O\u2019Bryant","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230317_ref5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial","volume":"68","author":"Lyketsos","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/JAD-230317_ref6","first-page":"243","article-title":"PRECISION MEDICINE - The Golden Gate for detection, treatment and prevention of Alzheimer\u2019s disease","volume":"3","author":"Hampel","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-230317_ref7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13697137.2017.1287866","article-title":"A Precision Medicine Initiative for Alzheimer\u2019s disease: The road ahead to biomarker-guided integrative disease modeling","volume":"20","author":"Hampel","year":"2017","journal-title":"Climacteric"},{"key":"10.3233\/JAD-230317_ref8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1377\/hlthaff.2018.0520","article-title":"Precision medicine","volume":"37","author":"Weil","year":"2018","journal-title":"Health Aff"},{"key":"10.3233\/JAD-230317_ref9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molmed.2015.05.003","article-title":"Clinical application of companion diagnostics","volume":"21","author":"J\u00f8rgensen","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.3233\/JAD-230317_ref10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1471-4914(01)01986-4","article-title":"Clinical application of pharmacogenetics","volume":"7","author":"Spear","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.3233\/JAD-230317_ref11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14737159.2015.1002470","article-title":"Companion diagnostics: The key to personalized medicine. Foreword","volume":"15","author":"J\u00f8rgensen","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"10.3233\/JAD-230317_ref12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230317_ref13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.parkreldis.2021.11.027","article-title":"Analysis of a precision medicine approach to treating Parkinson\u2019s disease: Analysis of the DATATOP study","volume":"94","author":"O\u2019Bryant","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JAD-230317_ref15","first-page":"83","article-title":"A blood screening test for Alzheimer\u2019s disease","volume":"3","author":"O\u2019Bryant","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230317_ref16","first-page":"374","article-title":"Potential two-step proteomic signature for Parkinson\u2019s disease: Pilot analysis in the Harvard Biomarkers Study","volume":"11","author":"O\u2019Bryant","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230317_ref17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3233\/JAD-141041","article-title":"Validation of a serum screen for Alzheimer\u2019s disease across assay platforms, species, and tissues","volume":"42","author":"O\u2019Bryant","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230317_ref18","first-page":"270","article-title":". A proteomic signature for dementia with Lewy bodies","volume":"11","author":"O\u2019Bryant","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230317_ref19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00994018","article-title":"Support-vector networks","volume":"20","author":"Cortes","year":"1995","journal-title":"Mach Learn"},{"key":"10.3233\/JAD-230317_ref20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00401-010-0723-9","article-title":"Biomarker discovery for Alzheimer\u2019s disease, frontotemporal lobar degeneration, and Parkinson\u2019s disease","volume":"120","author":"Hu","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230317_ref21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-014-1293-0","article-title":"Common mechanisms in neurodegeneration and neuroinflammation: A BrainNet Europe gene expression microarray study","volume":"122","author":"Durrenberger","year":"2015","journal-title":"J Neural Transm"},{"key":"10.3233\/JAD-230317_ref22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nri3705","article-title":"Innate immune activation in neurodegenerative disease","volume":"14","author":"Heneka","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.3233\/JAD-230317_ref23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13024-017-0216-6","article-title":"TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy","volume":"12","author":"Bemiller","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-230317_ref24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/1567205014666171004113537","article-title":"Reduced serotonin transporter levels and inflammation in the midbrain raphe of 12 month old APPswe\/PSEN1dE9 mice","volume":"15","author":"Metaxas","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-230317_ref25","doi-asserted-by":"crossref","first-page":"68654","DOI":"10.18632\/oncotarget.19818","article-title":"KRICT-9 inhibits neuroinflammation, amyloidogenesis and memory loss in Alzheimer\u2019s disease models","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.3233\/JAD-230317_ref26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3233\/JAD-170093","article-title":"Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of Alzheimer\u2019s disease","volume":"60","author":"Sundaram","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230317_ref27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.10265","article-title":"Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study","volume":"52","author":"Schmidt","year":"2002","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-230317_ref28","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1212\/WNL.54.11.2066","article-title":"Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study","volume":"54","author":"Anthony","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-230317_ref29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jnnp-2017-316201","article-title":"Peripheral inflammatory markers in Alzheimer\u2019s disease: A systematic review and meta-analysis of 175 studies","volume":"88","author":"Lai","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-230317_ref30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","article-title":"Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer\u2019s disease: Systematic review and meta-analysis of observational studies","volume":"327","author":"Etminan","year":"2003","journal-title":"BMJ"},{"key":"10.3233\/JAD-230317_ref31","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.3233\/JAD-230317_ref32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/alz.12382","article-title":"A blood screening tool for detecting mild cognitive impairment and Alzheimer\u2019s disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research","volume":"18","author":"O\u2019Bryant","year":"2022","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:30Z","timestamp":1777370910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-230317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":31,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-230317","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]}}}